Shares of Novo Nordisk A/S (NYSE:NVO - Get Free Report) crossed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $39.79 and traded as low as $39.32. Novo Nordisk A/S shares last traded at $39.49, with a volume of 16,550,286 shares trading hands.
Key Stories Impacting Novo Nordisk A/S
Here are a few of the latest stories about NVO:
Wall Street Analyst Weigh In
Several equities analysts recently commented on NVO shares. Berenberg Bank reissued a "neutral" rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Weiss Ratings downgraded shares of Novo Nordisk A/S from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Thursday, October 8th. UBS Group reiterated a "neutral" rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Barclays reissued a "neutral" rating on shares of Novo Nordisk A/S in a research report on Monday, September 7th. Finally, Jefferies Financial Group reaffirmed a "neutral" rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Five investment analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $59.44.
Get Our Latest Stock Report on NVO
Novo Nordisk A/S Stock Performance
The firm has a market cap of $176.32 billion, a price-to-earnings ratio of 9.95, a PEG ratio of 1.40 and a beta of 0.70. The company has a quick ratio of 0.64, a current ratio of 0.84 and a debt-to-equity ratio of 0.54. The company has a 50 day moving average of $39.79 and a 200 day moving average of $43.05.
Hedge Funds Weigh In On Novo Nordisk A/S
Several institutional investors and hedge funds have recently made changes to their positions in the business. Financial Freedom LLC bought a new position in Novo Nordisk A/S during the 3rd quarter valued at $30,000. Root Financial Partners LLC acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at about $32,000. Continuum Advisory LLC acquired a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at about $38,000. Latitude Advisors LLC bought a new position in shares of Novo Nordisk A/S during the third quarter worth about $38,000. Finally, Raffa Wealth Management LLC bought a new position in shares of Novo Nordisk A/S during the third quarter worth about $40,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.
Novo Nordisk A/S Company Profile
(
Get Free Report)
Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus. The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world. Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.